Abstract:Background One of the major challenges in the management of rheumatoid arthritis (RA) is to determine individual treatment and predict the prognosis. On a group level, high disease activity and antibodies specific for citrulline (ACPA) and immunoglobulins (RF) are factors associated with poor prognosis. New alternative biomarkers, which could provide more specific information, are antibodies to disease-related targets in the joints [1] Objectives To identify circulating autoantibodies to joint-related proteins (hereafter named JointIDs) that predict disease outcome in patients with new onset RA. Methods Sera at diagnosis from BARFOT and TIRA-2 cohorts (n=1986) with new onset RA patients were screened with a bead-based multiplex flow immunoassay to detect IgG autoantibodies against 47 peptides derived from joint proteins (JointIDs) (Lönnblom, under review 2023). Disease outcomes included Boolean remission at 6 and 12 months, swollen joint count (SJC) and radiological progression at 12 months (>8% affected feet joints and >3% affected hand joints) in patients who were without joint damage at inclusion. Multivariate logistic regression and zero-inflated negative binomial models adjusted for clinical factors (age, gender, ACPA, RF, changes in medication at 3 and 6 months) were used to identify JointIDs with the strongest potential to predict prognosis. Results Six JointIDs were identified as predictors for these disease outcomes in multivariate analyses. Presence of JointID178 predicted an average decrease in SJC at 6 months with 41% and with 33% at 12 months. Presence of at least 2 of the following factors: JointID178 positive and JointID199 negative at inclusion in combination with male sex identified approx. 40% of the patients in Boolean remission at 6 months with approx. 75% specificity (Table 1). A similar test performance was obtained even for Disease Activity Score 28 remission. The sensitivity and specificity for being in Boolean remission at 12 months if the patients were male, negative for JointID199 and in Boolean remission at 6 months was 13% (CI 9%;16%) and 99% (CI 99%;100%), respectively. RF and ACPA did not predict remission but were the strongest predictors of joint destruction at 12 months although with low specificity (58%). Addition of JointID166 significantly increased the specificity at the expense of sensitivity. Conclusion Autoantibodies to joint-related proteins at RA diagnosis can predict remission with a high specificity at 6 and 12 months. This knowledge is of clinical importance as patients positive or negative for these JointIDs in combination with clinical factors may potentially guide future treatment choices. Reference [1]Holmdahl R, Malmstrom V, Burkhardt H. Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Eur J Immunol 2014; 44(6): 1593-9. Acknowledgements: NIL. Disclosure of Interests Monica Leu Agelii: None declared, Outi Sareila Employee of: OS is an employee of Vacara AB, Erik Lönnblom Consultant of: EL is a consultant for Vacara AB, Kristina Forslind: None declared, Ingiäld Hafström: None declared, Maria Andersson: None declared, Alf Kastbom: None declared, Christopher Sjowall: None declared, Lennart T.H. Jacobsson Speakers bureau: Novartis, Eli-Lily and Janssen, Consultant of: Participated in Advisory Boards for Pfizer, Novartis, Eli-Lily and Janssen., Jan Kihlberg: None declared, Rikard Holmdahl Consultant of: Consulting fees from Regor, Lipum AB and Cyxone AB, Inger Gjertsson: None declared.

Inflammatory biomarkers predicting long-term remission and active disease in juvenile idiopathic arthritis: a population-based study of the Nordic JIA cohort

High-sensitive CRP as a predictive marker of long-term outcome in juvenile idiopathic arthritis

Gut Microbiota in Children with Juvenile Idiopathic Arthritis: Characteristics, Biomarker Identification, and Usefulness in Clinical Prediction.

Disease activity trajectories from childhood to adulthood in the population-based Nordic juvenile idiopathic arthritis cohort

Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis part 2: results of the Nordic model in the Canadian cohort

OP0123 AUTOANTIBODIES TO JOINT-RELATED PROTEINS PREDICT REMISSION IN NEW ONSET RA WITH HIGH SPECIFICITY

Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline

Serum and salivary inflammatory biomarkers in juvenile idiopathic arthritis—an explorative cross-sectional study

Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study

Autoantibodies to joint-related peptides as predictive markers in early rheumatoid arthritis

Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data

Treg fitness as a biomarker for disease activity in Juvenile Idiopathic Arthritis

OA02 Longitudinal high throughput proteomics identifies novel proteins associated with inflammation and future response in new-onset, treatment-naïve rheumatoid arthritis

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis

Predictors of fibrogenesis in children with JIA: a single-center pilot study

Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA

Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease

Inflammatory biomarkers and long-term outcome in young patients three months after a first myocardial infarction

Examining the Relationship between Systemic Immune–Inflammation Index and Disease Severity in Juvenile Idiopathic Arthritis

Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease